ReviewArthritis research & therapy2003
The use and abuse of commercial kits used to detect autoantibodies.
Review in Arthritis research & therapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.Annals of the rheumatic diseases · 2022Article
- Analysis of antinuclear antibody titers and patterns by using HEp-2 and primate liver tissue substrate indirect immunofluorescence assay in patients with systemic autoimmune rheumatic diseases.Journal of clinical laboratory analysis · 2020Article
- Single Cell Analysis of Neutrophils NETs by Microscopic LSPR Imaging System.Micromachines · 2019Article
- Antinuclear antibody testing in a Turkish pediatrics clinic: is it always necessary?The Pan African medical journal · 2019Article
- Next-Generation Autoantibody Testing by Combination of Screening and Confirmation-the CytoBead® Technology.Clinical reviews in allergy & immunology · 2017Review
- Determination of Anti-nuclear Antibody Pattern Distribution and Clinical Relationship.Pakistan journal of medical sciences · 2014Article
- The prevalence of antinuclear antibodies in patients with sarcoidosis.Autoimmune diseases · 2014Article
- An evaluation of autoimmune antibody testing patterns in a Canadian health region and an evaluation of a laboratory algorithm aimed at reducing unnecessary testing.Clinical rheumatology · 2013Article
- Missing links in high quality diagnostics of inflammatory systemic rheumatic diseases: It is all about the patient!Auto- immunity highlights · 2012Review
- Need for an Ethical Framework for Testing for Systemic Diseases in Dental Clinics.Ethics in biology, engineering & medicine · 2011Article
- A proposed model for effective collaboration between rheumatologists and clinical pathologists for the diagnosis of autoimmune rheumatic diseases.Rheumatology international · 2009Article
- Autoimmune liver serology: current diagnostic and clinical challenges.World journal of gastroenterology · 2008Review
- [Diagnostic strategies for autoimmune rheumatic diseases].Zeitschrift fur Rheumatologie · 2007Review
- Guidelines for Antinuclear Antibody Testing.EJIFCC · 2006Article
- The nuclear pore complex protein Tpr is a common autoantigen in sera that demonstrate nuclear envelope staining by indirect immunofluorescence.Clinical and experimental immunology · 2004Article
- Technical and clinical evaluation of anti-ribosomal P protein immunoassays.Journal of clinical laboratory analysis · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The detection of autoantibodies in human sera is an important approach to the diagnosis and management of patients with autoimmune conditions. To meet market demands, manufacturers have developed a wide variety of easy to use and cost-effective diagnostic kits that are designed to detect a variety of human serum autoantibodies. A number of studies over the past two decades have suggested that there are limitations and concerns in the use and clinical application of test results derived from commercial kits. It is important to appreciate that there is a complex chain of users and circumstances that contributes to variations in the apparent reliability of commercial kits. The goal of this review is to identify the principal links in this chain, to identify the factors that weaken the chain and to propose a plan of resolution. It is suggested that a higher level of commitment and partnership between all of the participants is required to achieve the goal of improving the quality of patient care through the use of autoantibody testing and analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.